Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with issue proceeds of approximately SEK 300 million before deduction of transaction costs.
Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.
Vinge’s team consisted of Dain Hård Nevonen, William Kåge, Joel Magnusson, Annie Fällström and Maximilian Bengtsson.
